Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2026)
Sarepta Therapeutics' quarterly Gross Margin came in at 72.83% in Q1 2026, up 7600.0% year-on-year from 0.95% in Q1 2025, and up 629.39% quarter-over-quarter from 9.98% in Q4 2025.
Sarepta Therapeutics has reported Gross Margin for 10 years, with the latest figure at 72.83% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 7600.0% year-over-year to 72.83%; the trailing twelve-month figure through Mar 2026 stood at 56.26% (down 1870.0% YoY), and the FY2025 full-year result was 61.81%, down 2142.0% from the prior year.
- Gross Margin for Q1 2026 stood at 72.83%, up from 9.98% in the prior quarter.
- The five-year high for Gross Margin was 90.47% in Q4 2023, with the low at 53.37% in Q2 2023.
- Average Gross Margin over 5 years is 56.86%, with a median of 80.37% recorded in 2024.
- Year-over-year, Gross Margin tumbled 13547 bps in 2023 and soared 14109 bps in 2024.
- Tracing SRPT's Gross Margin over 5 years: stood at 81.8% in 2022, then gained by 11 bps to 90.47% in 2023, then retreated by 12 bps to 79.91% in 2024, then sank by 88 bps to 9.98% in 2025, then surged by 629 bps to 72.83% in 2026.
- The last three Gross Margin figures came in at 72.83% (Q1 2026), 9.98% (Q4 2025), and 62.25% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 72.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.83% |
| Dec 31, 2025 | 9.98% |
| Sep 30, 2025 | 62.25% |
| Jun 30, 2025 | 75.04% |
| Mar 31, 2025 | -3.17% |
| Dec 31, 2024 | 79.91% |
| Sep 30, 2024 | 80.37% |
| Jun 30, 2024 | 87.73% |
| Mar 31, 2024 | 87.77% |
| Dec 31, 2023 | 90.47% |
| Sep 30, 2023 | 88.84% |
| Jun 30, 2023 | -53.37% |
| Mar 31, 2023 | 86.19% |
| Dec 31, 2022 | 81.80% |
| Sep 30, 2022 | 80.77% |
| Jun 30, 2022 | 82.10% |
| Mar 31, 2022 | -42.89% |
| Dec 31, 2021 | 71.65% |
| Sep 30, 2021 | 87.62% |
| Jun 30, 2021 | 86.24% |
| Mar 31, 2021 | 84.79% |
| Dec 31, 2020 | 0.40% |
| Sep 30, 2020 | 33.25% |
| Jun 30, 2020 | 48.73% |
| Mar 31, 2020 | 4.57% |
| Dec 31, 2019 | 84.45% |
| Sep 30, 2019 | 86.84% |
| Jun 30, 2019 | 83.18% |
| Mar 31, 2019 | 86.14% |
| Dec 31, 2018 | 84.44% |
| Sep 30, 2018 | 88.86% |
| Jun 30, 2018 | 90.84% |
| Mar 31, 2018 | 91.36% |
| Dec 31, 2017 | 93.81% |
| Sep 30, 2017 | 93.30% |
| Jun 30, 2017 | 98.56% |
| Mar 31, 2017 | 98.63% |